ArticleFrontiers in pharmacology2022
Insulin degludec/liraglutide versus its monotherapy on T2D patients: A lifetime cost-utility analysis in China.
Guangxin Han et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it